NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
RANEXA (ranolazine) by Menarini is cytochrome p450 3a inhibitors [moa]. First approved in 2006.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RANEXA (ranolazine) is an oral extended-release tablet approved in 2006 for chronic angina management. It works as a cytochrome P450 3A inhibitor to reduce anginal symptoms and improve exercise tolerance. It is used as an adjunctive anti-anginal agent in patients inadequately controlled by conventional therapies.
$2MPart D
LOE ApproachingMature product with declining Medicare utilization signals contraction; reduced team expansion opportunities as LOE approaches.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Oral Tranexamic Acid Plus Triple Combination vs Triple Combination Alone in Melasma
Started Jul 2026
128 enrolled
MelasmaMelasma (Facial Melasma)
Comparative Efficacy of Intralesional Tranexamic Acid Versus Mandelic Acid Peel in the Treatment of Melasma
Started May 2026
120 enrolled
Melasma
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
Started Nov 2025
1,546 enrolled
Liver TransplantationTranexamic AcidEnd-stage Liver Disease (ESLD)
Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery
Started Jun 2024
850 enrolled
Surgical Blood LossTransfusion-dependent AnemiaAbdomen Disease
Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
Started Jan 2024
65 enrolled
BleedingContraceptive Device; Complications
Worked on RANEXA at Menarini? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.